Shots:

• Qpex Biopharm to receive up front- development- regulatory and commercial milestones with royalties on sales in the licensed territories. Brii Biosciences to get the license to develop- manufacture- and commercialize Qpex's antibiotic portfolio in China including Taiwan- Hong Kong- Macau and the People's Republic of China
• The Qpex’s portfolio includes OMNIvance- ORAvance and a next-generation Polymyxin to treat MDR gram-negative infections. The companies will share the global development cost of the products
•  OMNIvance and ORAvance utilizes Qpex's beta-lactamase inhibitor QPX7728 that inhibits both serine and metallo beta-lactamases- while next-generation polymyxin (IV) targets spectrum synthetic polymyxin with enhanced therapeutic profile addressing the infection caused by Pseudomonas and Acinetobacter

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Brii Biosciences